In a COPD patient with an acute exacerbation on doxycycline and prednisolone, which change would optimally optimize therapy?

• A. Continue Ultibro Breezhaler as prescribed
• B. Switch to Trimbow 87/5/9 - 2 puffs BD
• C. Add a macrolide antibiotic
• D. Initiate long-term oxygen therapy

Answer: (B)

Escalating inhaled therapy to include an anti-inflammatory component is the key idea when a COPD patient on dual bronchodilation continues to have an acute exacerbation. Replacing the current inhaler with a triple-therapy inhaler that combines an inhaled corticosteroid with a LABA and a LAMA delivers immediate bronchodilation plus targeted airway inflammation control. This dual approach reduces the inflammatory burden in the airways during an exacerbation and lowers the risk of future exacerbations, and the specific regimen of budesonide/formoterol/glycopyrronium given as two puffs twice daily provides consistent, practical daily exposure to all three agents.

Continuing only the current dual bronchodilator misses the anti-inflammatory benefit, which is particularly important during an exacerbation when inflammation drives symptoms and complication risk. Adding a macrolide antibiotic isn’t the most immediate optimization here, especially since an antibiotic already given and long-term macrolide prophylaxis carries additional risks. Initiating long-term oxygen therapy isn’t indicated unless there is chronic hypoxemia, rather than a general step-up during an exacerbation.